In models of non-alcoholic steatohepatitis, CAG not only reduces hepatic steatosis but also inhibits the progression of liver fibrosis by decreasing the expression of CK19 and α-SMA, which are likely achieved through FXR-mediated anti-inflammatory and anti-fibrotic effects (Gu et al., 2017). The gene discussed is NR1H4; the disease is Hepatic fibrosis.